Full-Time

Program Implementation Manager

Clinical Studies

Deadline 1/7/27
American Heart Association

American Heart Association

5,001-10,000 employees

Compensation Overview

$70k - $90k/yr

Dallas, TX, USA + 3 more

More locations: Philadelphia, PA, USA | Chicago, IL, USA | New York, NY, USA

Remote

Home-based role; up to 15% national travel with overnight stays.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s Degree
  • Three (3) years of relevant experience
  • Experience interacting and engaging with clinicians and C-suite, ideally in a hospital setting
  • Experience communicating complex information and directions to varying levels of health care professionals and leadership
  • Strong verbal, written, and presentation communications skills, including communication with clinical leadership
  • Experience in healthcare or in a public health-related organization, clinical studies, clinical registries, patient registries, or quality improvement programs
  • Experience with program/project management, including experience in influencing performance without direct line accountability
  • Experience with account management and sales success/business development
  • Ability to function and drive work independently with minimal supervision
  • Experience with Microsoft Office suite skills, including Word, Excel, PowerPoint, and Outlook
  • Ability to work in a team environment and interact with all levels of American Heart Association staff, volunteers, and the public
  • Ability to travel up to 15% nationally with overnight stay
Responsibilities
  • Leverage available data to identify and develop pipeline of prospective hospitals and associated clinics for clinical trial patient referrals in a variety of Cardiovascular Diseases trials. Cultivate and manage relationships to achieve program goals.
  • Oversee and coordinate the full site activation lifecycle, including trial site contracting, regulatory onboarding, and required documentation.
  • Prospect new hospitals and associated clinics by working with established customers, routinely reviewing their data, consulting on identification of patients and clearly conveying the referral process to all involved site staff
  • Serve as main account manager of participating sites. Onboard and train participating sites, providing education on protocol requirements, data collection, reporting expectations, and regulatory obligations; manage and consult sites on both site-level and system-level responsibilities
  • Ensure accuracy in information collected and oversee ongoing regulatory compliance and monitoring activities across trial sites, including internal tracking, regulatory documentation, and information shared with stakeholders
  • Routinely meet with and visit sites to boost patient referrals, focusing on gaining a deep understanding of care pathways and optimizing workflows
  • Lead and manage patient recruitment, enrollment, and retention strategies across trial sites, including outreach, screening, follow-up operations, and proactive troubleshooting of barriers; monitor performance and provide regular progress updates to trial leadership
  • Serve as the primary patient liaison throughout the clinical trial lifecycle, addressing barriers to participation, supporting long-term engagement, and sharing actionable insights with leadership to enhance patient experience and study outcomes
  • Assess each site’s clinical research team’s patient recruitment and retention success and offer suggestions for process improvement
  • Develop and deliver education toolkit and training materials to trial hospitals, field staff and other departments, ensuring you are always providing tangible solutions to overcome their evolving barrier(s)
  • Establish and conduct related data monitoring activities including patient volume, referral tracking, data entry, engagement, data completion, data quality and patient and clinician barriers
  • Develop and deliver site and program-wide targeted education and training materials, utilizing collected insights; this includes fully developing and implementing national educational webinars for clinicians and healthcare leadership, researching and creating patient and clinician educational materials, etc.
  • Identify, build, cultivate and manage key high-level partner and customer relationships to achieve program goals. Collaborate with any related project Committees, and other high-level physicians and C-suite members from participating sites and stakeholders
  • Analyze, collate, and present results of training, education, and data to continually evaluate next steps and needs for program. Address any inconsistencies appropriately and within a timely manner
  • Communicate regularly with Project leadership to ensure tasks are completed according to project timeline. Routinely prepare and present findings to internal and external project leadership. Work with colleagues and external partners through ongoing meetings to report out on project deliverables
  • Attend site meetings, project-level meetings, leadership meetings, and related scientific conferences
  • Serve as the primary point of contact for sites throughout the trial lifecycle, from initial engagement through closeout, ensuring strong collaboration, timely issue resolution, and adherence to study requirements
  • Other duties as assigned by the Supervisor, including additional trial support on other projects
Desired Qualifications
  • Master’s degree
  • Knowledge of clinical trial operations, preferably from a sponsor perspective
  • Knowledge of Cardiovascular Diseases
American Heart Association

American Heart Association

View

Company Size

5,001-10,000

Company Stage

Grant

Total Funding

$700K

Headquarters

Dallas, Texas

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Heart Walk, Kids Heart Challenge rank top 5 U.S. fundraisers nationally.
  • Global expansion via CPR guidelines forums across MENA, India, Japan.
  • Corporate partnerships with Alnylam, Charles River accelerate research and awareness.

What critics are saying

  • Corporate sponsor dependence undermines independence; Alnylam partnership promotes proprietary drugs.
  • New dietary guidelines face backlash, eroding credibility with health professionals.
  • $20M Fontan program risks failure to deliver monitoring tools, damaging reputation.

What makes American Heart Association unique

  • Largest nonprofit cardiovascular research funder with 100+ year track record.
  • 35 million global volunteers amplify reach beyond traditional nonprofit scale.
  • Convenes multidisciplinary health systems for care coordination and quality improvement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Employee Assistance Program

Wellness Program

Telemedicine

Tuition Reimbursement

Paid Vacation

Paid Holidays

Hybrid Work Options

Remote Work Options

Company News

Contract Pharma
Apr 10th, 2026
Charles River, American Heart Association partner to advance cardiovascular health awareness.

Charles River, American Heart Association partner to advance cardiovascular health awareness. Charles River to support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. April 10, 2026 Associate Editor Charles River Laboratories International Inc. has partnered with the American Heart Association to support cardiovascular disease awareness, prevention, and community health initiatives. Through this collaboration, Charles River will support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." The joint effort comes at a critical time for public health. According to the American Heart Association's recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in the United States, while stroke is now the fourth-leading cause of death. Together, heart disease and stroke account for more than one in four U.S. deaths, despite recent improvements in overall cardiovascular mortality. While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association's update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health. More Charles River news. Therna Biosciences, a biotechnology company pioneering programmable RNA therapeutics, recently joined forces with Charles River to advance single-patient RNA medicines for individuals with severe, ultra-rare disorders.

HealthTech HotSpot
Apr 9th, 2026
Charles River advances cardiovascular health awareness Through support of the American Heart Association.

Charles River advances cardiovascular health awareness Through support of the American Heart Association. WILMINGTON, Mass.-(BUSINESS WIRE)-$CRL #CDMO-Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." Through this collaboration, Charles River will support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. The support reinforces shared commitments to science-driven progress, prevention, and community engagement, and aligns with Charles River's corporate purpose - Together, HealthTech HotSpot LLC Create Healthier Lives - and its Corporate Citizenship strategy focused on advancing human health beyond the laboratory. The joint effort comes at a critical time for public health. According to the American Heart Association's recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in the United States, while stroke is now the fourth-leading cause of death. Together, heart disease and stroke account for more than one in four U.S. deaths, despite recent improvements in overall cardiovascular mortality. While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association's update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more, visit www.criver.com. Charles River Investor Contact: Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected] Charles River Media Contact: Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer 781.222.6168 [email protected] April 10th, 2026 April 9th, 2026

Business Insider
Apr 7th, 2026
SimpliFed raises $10.8M Series A to expand virtual maternal health platform from lactation to full OB care

SimpliFed, a virtual maternal healthcare platform, has raised $10.8 million in an oversubscribed Series A round led by Morningside and Hesperia Capital. Foreground Capital and existing investors including AHA Social Impact Fund and Elizabeth Street Ventures participated. The company, which provides virtual breastfeeding and baby feeding support, is expanding into virtual OB services to offer prenatal and postpartum care for low-risk patients. SimpliFed connects families with certified lactation consultants and maternal health providers through telehealth visits, integrating with major electronic medical record systems. SimpliFed is on track to serve 5% of all US births in 2026 and is in network with major commercial health plans and Medicaid across several states. The funding will support growth of its Maternal Health Operating System and partnerships with health systems and OBGYN clinics.

American Heart Association
Mar 30th, 2026
New $20M effort aims to address critical gaps in care for people with single ventricle heart disease.

New $20M effort aims to address critical gaps in care for people with single ventricle heart disease. The American Heart Association and Additional Ventures develop program focused on improving long-term health for people living with Fontan circulation DALLAS, March 30, 2026 - The lifesaving surgery used to treat children with single ventricle heart disease, the Fontan procedure, can pose serious health complications throughout life. The American Heart Association, devoted to changing the future to a world of healthier lives for all and Additional Ventures, a research foundation working toward a cure for single ventricle heart disease, have committed a combined $20M to advance a coordinated, collaborative approach to improving the ability to predict, prevent and treat health complications in people living with Fontan circulation. Single ventricle heart disease affects about 6 in 10,0000 babies born in the US each year[1]. These children are born with only one working heart pump and must rely on a surgically created circulation (the Fontan circulation) to reroute blood through the body. While lifesaving, this circulation places long-term strain on the body and can lead to progressive damage across multiple organs. Today, clinicians lack reliable ways to monitor Fontan health, making them unable to detect early signs of decline. As a result, many patients appear stable until they suddenly experience severe complications that can be fatal or severely impact quality of life. The program will bring together clinicians, researchers and patients to generate scientific and clinical insights and develop tools to better guide care for people living with Fontan circulation. The program combines the strength of the American Heart Association's research infrastructure, guideline development, data coordination and registry science with Additional Ventures' leadership in single ventricle strategy, deep scientific expertise and unparalleled network across the single ventricle heart disease ecosystem. "People with Fontan circulation often develop complications with other organs in the body including the liver, kidneys and lungs," said Mariell Jessup, M.D., FAHA, chief medical and science officer of the American Heart Association. "The coordination between our two organizations will generate data and insight that can help patients and clinicians better monitor their health and intervene earlier." "While lifesaving, Fontan circulation creates complex, lifelong health challenges for single ventricle heart disease patients that we still do not fully understand," said Kirstie Keller, PhD, chief executive officer of Additional Ventures. "Through this collaboration, we will work with researchers, clinicians and patients to generate the scientific insights and tools needed to predict, detect and manage complications earlier. By building these resources, we hope to enable a more proactive, science-informed approach to lifelong care for Fontan patients. The six-year, multi-phase strategy begins with evaluating current approaches to monitoring Fontan circulation patients; identifying gaps in care, data and infrastructure; and engaging patients, clinicians and scientists in program design and implementation. Ultimately, the goal is to establish the scientific foundation and clinical tools needed to move the field from reactive care to proactive health monitoring of patients with Fontan circulation, creating the infrastructure for a future standard of care. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1. About Additional Ventures Additional Ventures is a research foundation committed to curing single ventricle heart disease through transformative research and strategic investments that revolutionize treatment and care. By combining deep scientific expertise with strategic, flexible funding, Additional Ventures supports bold, collaborative research across the translational pipeline. Since its founding in 2020, Additional Ventures has committed more than $110 million to single ventricle heart disease research. Learn more about our work and progress in our most recent Impact Report, at additionalventures.org, or by following us on LinkedIn. For Media Inquiries: 214-706-1173 For Public Inquiries: 1-800-AHA-USA1 (242-8721)

CBS News
Mar 29th, 2026
New heart health dietary guidelines.

New heart health dietary guidelines. The American Heart Association has released new dietary guidelines on how to stay heart healthy to improve quality of life and save lives. Dr. Celine Gounder breaks down what to know. 4h ago Around the web. 60 minutes.